{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:29:06Z","timestamp":1790623746347,"version":"4.1.0"},"reference-count":96,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH\/NCI Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"crossref","award":["T32GM007739"],"award-info":[{"award-number":["T32GM007739"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Memorial Sloan Kettering Cancer Center Grayer Fellowship"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1F30CA284575-01A1"],"award-info":[{"award-number":["1F30CA284575-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ASH Graduate Hematology Award"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a molecularly heterogeneous neoplasm of hematopoietic stem and progenitor cells. The advent of high-resolution genomic sequencing has uncovered several genetic drivers of AML which spurred a surge of therapies that target the disease at a mutational, clonal, or epigenetic level. Currently, the molecular profiling of AML patients before treatment is commonplace and crucial for ensuring that patients receive the most optimal therapy for any driver mutations they may have. Here, we detail the current targeted therapies available for AML: specifically, those targeting the BCL2 family (venetoclax), FLT3 (midostaurin, gilteritinib, quizartinib), IDH1\/2 (enasidenib, ivosidenib), and MENIN (revumenib, ziftomenib). In addition, we outline potential mechanisms of resistance against these therapies, as well as efforts being taken to prevent or bypass them.<\/jats:p>","DOI":"10.3390\/jpm16030169","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:44:46Z","timestamp":1774007086000},"page":"169","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5154-0232","authenticated-orcid":false,"given":"Kaitlyn H.","family":"Ko","sequence":"first","affiliation":[{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7270-8249","authenticated-orcid":false,"given":"Rebecca","family":"Gelfer","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0018-4981","authenticated-orcid":false,"given":"Justin C.","family":"Wheat","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2708-887X","authenticated-orcid":false,"given":"Sheng F.","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/sj.leu.2401573","article-title":"Expression of Bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid","volume":"13","author":"Andreeff","year":"1999","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2141.2002.03637.x","article-title":"The anti-apoptotic genes Bcl-XL and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells","volume":"118","author":"Konopleva","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed\/Refractory Acute Myeloid Leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A Phase Ib\/II Study of Ivosidenib with Venetoclax \u00b1 Azacitidine in IDH1-Mutated Myeloid Malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2024-200393","article-title":"A Phase Ib\/II Study of Ivosidenib with Venetoclax \u00b1 Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update","volume":"144","author":"Garcia","year":"2024","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: A multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-24-0028","article-title":"A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed\/Refractory Hematologic Malignancies","volume":"30","author":"Desai","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"eabo6891","DOI":"10.1126\/scitranslmed.abo6891","article-title":"The path to venetoclax resistance is paved with mutations, metabolism, and more","volume":"14","author":"Sullivan","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1158\/1078-0432.CCR-21-4037","article-title":"Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood-2025-1641","article-title":"Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax\u2013exposed myeloid malignancies","volume":"146","author":"Kadia","year":"2025","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood-2025-663","article-title":"Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1\/2 study","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1182\/blood-2024-205980","article-title":"Phase 1 Trial of Navitoclax\/Venetoclax\/Decitabine Combination in Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML)","volume":"144","author":"Stein","year":"2024","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100905","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0092-8674(91)90010-V","article-title":"A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations","volume":"65","author":"Matthews","year":"1991","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0092-8674(93)90325-K","article-title":"Molecular cloning of a ligand for the flt3 flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells","volume":"75","author":"Lyman","year":"1993","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/sj.leu.2401130","article-title":"Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product","volume":"12","author":"Kiyoi","year":"1998","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Janke, H., Pastore, F., Schumacher, D., Herold, T., Hopfner, K.P., Schneider, S., Berdel, W.E., Buchner, T., Woermann, B.J., and Subklewe, M. (2014). Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089560"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","article-title":"FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia","volume":"110","author":"Mead","year":"2007","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2007-08-107946","article-title":"FLT3 D835\/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications","volume":"111","author":"Whitman","year":"2008","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Li, S., Li, N., Chen, Y., Zheng, Z., and Guo, Y. (2023). FLT3-TKD in the prognosis of patients with acute myeloid leukemia: A meta-analysis. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1086846"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1182\/blood.V88.12.4493.bloodjournal88124493","article-title":"Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia","volume":"88","author":"Lyman","year":"1996","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/blood-2009-09-242859","article-title":"FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML","volume":"115","author":"Pratz","year":"2010","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood-2016-09-693648","article-title":"How I treat FLT3-mutated AML","volume":"129","author":"Pratz","year":"2017","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/blood-2021-145379","article-title":"Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1080\/10428194.2019.1602263","article-title":"FLT3 inhibitor quizartinib (AC220)","volume":"60","author":"Naqvi","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N\u2032-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_55","first-page":"254","article-title":"Prognostic significance of IDH1 mutations in acute myeloid leukemia: A meta-analysis","volume":"2","author":"Feng","year":"2012","journal-title":"Am. J. Blood Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41375-024-02246-2","article-title":"Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia","volume":"38","author":"Fruchtman","year":"2024","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: A randomized phase 3 trial","volume":"141","author":"Montesinos","year":"2023","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2023010563","article-title":"A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML","volume":"8","author":"Cai","year":"2024","journal-title":"Blood Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e887","DOI":"10.1016\/S2352-3026(25)00254-6","article-title":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): A multicentre, single-arm, phase 1b\/2 trial","volume":"12","author":"Gupta","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","article-title":"Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","article-title":"Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations","volume":"559","author":"Intlekofer","year":"2018","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e20200924","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1182\/bloodadvances.2025016399","article-title":"Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML","volume":"9","author":"Montesinos","year":"2025","journal-title":"Blood Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-025-01751-w","article-title":"Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort","volume":"18","author":"Cortes","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00432-022-03983-6","article-title":"A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome","volume":"149","author":"DiNardo","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1038\/s41375-020-0996-5","article-title":"Safety and efficacy of BAY1436032 in IDH1-mutant AML: Phase I study results","volume":"34","author":"Heuser","year":"2020","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"10632","DOI":"10.1073\/pnas.95.18.10632","article-title":"MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis","volume":"95","author":"Yu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.exphem.2016.10.014","article-title":"Transcriptional activation by MLL fusion proteins in leukemogenesis","volume":"46","author":"Yokoyama","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ydbio.2005.01.004","article-title":"The homeodomain protein Meis1 is essential for definitive hematopoiesis and vascular patterning in the mouse embryo","volume":"280","author":"Azcoitia","year":"2005","journal-title":"Dev. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.emboj.7600038","article-title":"Hematopoietic, angiogenic and eye defects in Meis1 mutant animals","volume":"23","author":"Hisa","year":"2004","journal-title":"EMBO J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/0008-5472.CAN-06-2369","article-title":"Interaction of MLL amino terminal sequences with menin is required for transformation","volume":"67","author":"Caslini","year":"2007","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia","volume":"6","author":"Kuhn","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MOH.0000000000000796","article-title":"The future of HOXA-expressing leukemias: Menin inhibitor response and resistance","volume":"31","author":"Wenge","year":"2024","journal-title":"Curr. Opin. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2024-194384","article-title":"Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R\/R) KMT2Ar Acute Leukemia","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: The AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in Relapsed or Refractory NPM1-Mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition","volume":"13","author":"Perner","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.seminhematol.2018.08.001","article-title":"Genetic and epigenetic determinants of AML pathogenesis","volume":"56","author":"Cai","year":"2019","journal-title":"Semin. Hematol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/3\/169\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T05:29:15Z","timestamp":1774157355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/3\/169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":96,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jpm16030169"],"URL":"https:\/\/doi.org\/10.3390\/jpm16030169","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]}}}